Coya Therapeutics Inc (COYA)

May 16, 2025

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire

May 16, 2025

May 16, 2025

Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Holdings Lifted by Tower Research Capital LLC TRC - Defense World

May 16, 2025

May 14, 2025

Coya Therapeutics (COYA): Analyst Maintains Buy Rating and Price - GuruFocus

May 14, 2025

May 14, 2025

Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World

May 14, 2025

May 14, 2025

Coya Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 14, 2025

May 13, 2025

Coya (COYA) Reports Lower Q1 Revenue Than Expected | COYA Stock News - GuruFocus

May 13, 2025

May 13, 2025

Coya Therapeutics (COYA) Reports Q1 EPS and Cash Position - GuruFocus

May 13, 2025

May 13, 2025

Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025

May 13, 2025

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire

May 13, 2025

May 08, 2025

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Stock Titan

May 08, 2025

May 07, 2025

Coya Therapeutics (COYA) Projected to Post Quarterly Earnings on Thursday - Defense World

May 07, 2025

May 05, 2025

How To Trade (COYA) - news.stocktradersdaily.com

May 05, 2025

May 02, 2025

Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Geode Capital Management LLC - Defense World

May 02, 2025

May 01, 2025

Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN

May 01, 2025

Apr 29, 2025

Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Apr 29, 2025

Apr 29, 2025

Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World

Apr 29, 2025

Apr 25, 2025

Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com

Apr 25, 2025

Apr 25, 2025

Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha

Apr 25, 2025

Apr 24, 2025

Coya Therapeutics Announce Positive Interim Result from - openPR.com

Apr 24, 2025

Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com

Apr 24, 2025

Apr 24, 2025

Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com

Apr 24, 2025

Apr 24, 2025

Coya stock in focus after interim results for dementia drug - Seeking Alpha

Apr 24, 2025

Apr 24, 2025

Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq

Apr 24, 2025

Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph

Apr 24, 2025

Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com

Apr 24, 2025

Apr 24, 2025

Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan

Apr 24, 2025

Apr 24, 2025

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World

Apr 24, 2025

Apr 23, 2025

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance

Apr 23, 2025

Apr 22, 2025

AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com

Apr 22, 2025

Apr 22, 2025

Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World

Apr 22, 2025

Apr 21, 2025

Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Breakthrough: New GLP-1/IL-2 Combo Drug Outperforms Standard Therapy by 42% in Alzheimer's Research - Stock Titan

Apr 21, 2025

Apr 20, 2025

(COYA) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 20, 2025

Apr 11, 2025

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo

Apr 11, 2025

Apr 10, 2025

Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada

Apr 09, 2025

Apr 03, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Apr 03, 2025

Apr 02, 2025

Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com

Apr 02, 2025

Apr 01, 2025

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe

Apr 01, 2025

Mar 31, 2025

GMP Production of Exosomes Slated for Later This Year - streetwisereports.com

Mar 31, 2025

Mar 29, 2025

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World

Mar 29, 2025

Mar 28, 2025

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports

Mar 28, 2025

Mar 28, 2025

What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World

Mar 28, 2025

Mar 27, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025